USD 0.55
(-2.7%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | 34.3 Million USD | 405.28% |
2022 | -11.23 Million USD | 50.49% |
2021 | -22.7 Million USD | 33.93% |
2020 | -34.36 Million USD | -211.98% |
2019 | 30.68 Million USD | 78.56% |
2018 | 17.18 Million USD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q3 | 30.55 Million USD | 58.27% |
2024 Q2 | 19.3 Million USD | -61.07% |
2024 Q1 | 49.58 Million USD | 44.53% |
2023 Q3 | 30.9 Million USD | 11.94% |
2023 FY | 34.3 Million USD | 405.28% |
2023 Q4 | 34.3 Million USD | 11.0% |
2023 Q2 | 27.61 Million USD | 102.13% |
2023 Q1 | 13.66 Million USD | 221.55% |
2022 Q2 | 998 Thousand USD | 124.74% |
2022 Q1 | -4.03 Million USD | 82.23% |
2022 FY | -11.23 Million USD | 50.49% |
2022 Q4 | -11.23 Million USD | -234.91% |
2022 Q3 | 8.33 Million USD | 734.67% |
2021 Q1 | -22.29 Million USD | 35.12% |
2021 FY | -22.7 Million USD | 33.93% |
2021 Q4 | -22.7 Million USD | -26.69% |
2021 Q3 | -17.91 Million USD | 23.06% |
2021 Q2 | -23.28 Million USD | -4.46% |
2020 Q2 | 15.64 Million USD | 195.97% |
2020 Q4 | -34.36 Million USD | -171.9% |
2020 Q3 | 47.78 Million USD | 205.46% |
2020 FY | -34.36 Million USD | -211.98% |
2020 Q1 | 5.28 Million USD | -82.77% |
2019 FY | 30.68 Million USD | 78.56% |
2019 Q4 | 30.68 Million USD | 0.0% |
2019 Q1 | 5.91 Million USD | 0.0% |
2018 FY | 17.18 Million USD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Aclaris Therapeutics, Inc. | -39.45 Million USD | 186.959% |
Applied DNA Sciences, Inc. | -5.91 Million USD | 680.094% |
Aspira Women's Health Inc. | -331 Thousand USD | 10464.653% |
BioNexus Gene Lab Corp. | -5.79 Million USD | 691.914% |
bioAffinity Technologies, Inc. | -1.24 Million USD | 2860.169% |
bioAffinity Technologies, Inc. | -1.24 Million USD | 2860.169% |
Bionano Genomics, Inc. | 34.88 Million USD | 1.648% |
CareDx, Inc | -47.97 Million USD | 171.509% |
Check-Cap Ltd. | -24.75 Million USD | 238.581% |
Castle Biosciences, Inc. | -83.53 Million USD | 141.071% |
DarioHealth Corp. | -7.54 Million USD | 554.518% |
Exact Sciences Corporation | 1.94 Billion USD | 98.24% |
Fulgent Genetics, Inc. | -82.56 Million USD | 141.551% |
Guardant Health, Inc. | 220.22 Million USD | 84.422% |
ICON Public Limited Company | 3.56 Billion USD | 99.036% |
IDEXX Laboratories, Inc. | 493.94 Million USD | 93.055% |
Illumina, Inc. | 1.21 Billion USD | 97.174% |
Intelligent Bio Solutions Inc. | -5.43 Million USD | 731.496% |
iSpecimen Inc. | -2.14 Million USD | 1697.59% |
Standard BioTools Inc. | 46.5 Million USD | 26.231% |
MDxHealth SA | 18.88 Million USD | -81.663% |
23andMe Holding Co. | -141.37 Million USD | 124.267% |
Medpace Holdings, Inc. | -103.32 Million USD | 133.202% |
Myriad Genetics, Inc. | 88.1 Million USD | 61.059% |
Mainz Biomed B.V. | 349.85 Thousand USD | -9706.063% |
ENDRA Life Sciences Inc. | -2.43 Million USD | 1506.31% |
NeoGenomics, Inc. | 269.19 Million USD | 87.256% |
Neogen Corporation | 735.62 Million USD | 95.336% |
Inotiv, Inc. | 382.14 Million USD | 91.023% |
Natera, Inc. | -200.1 Million USD | 117.145% |
OpGen, Inc. | 11.89 Million USD | -188.491% |
OPKO Health, Inc. | 230.68 Million USD | 85.128% |
Psychemedics Corporation | 334 Thousand USD | -10171.557% |
Prenetics Global Limited | -43.33 Million USD | 179.163% |
Prenetics Global Limited | -43.33 Million USD | 179.163% |
Precipio, Inc. | -386 Thousand USD | 8987.824% |
Personalis, Inc. | -8.02 Million USD | 527.661% |
RadNet, Inc. | 1.14 Billion USD | 97.013% |
Sera Prognostics, Inc. | -2.02 Million USD | 1796.686% |
Sotera Health Company | 2.02 Billion USD | 98.306% |
Neuronetics, Inc. | 2.79 Million USD | -1126.564% |
Star Equity Holdings, Inc. | -15.33 Million USD | 323.688% |
Star Equity Holdings, Inc. | -15.33 Million USD | 323.688% |
Trinity Biotech plc | 63.73 Million USD | 46.173% |
T2 Biosystems, Inc. | 33.8 Million USD | -1.473% |
Twist Bioscience Corporation | -192.4 Million USD | 117.831% |
Exagen Inc. | -12.77 Million USD | 368.611% |